Novo Nordisk: Novo Nordisk Shares Data From Injectable Ozempic, Oral Weight Loss Drug
Novo Nordisk's Phase 3b STRIDE trial shows Ozempic improves walking distance in peripheral artery disease, while the SOUL trial finds Rybelsus lowers cardiovascular risk by 14%. read more
Read full article »
Novo Nordisk is a Denmark-based multinational pharmaceutical company that develops and commercializes diabetes care medications and devices for the healthcare industry.
Read more